Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Nimodipine

A dihydropyridine calcium channel blocker patented in 1971 and approved in Germany in 1985; it is used to prevent cerebral vasospasm after a subarachnoid haemorrhage from a ruptured aneurysm. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It was developed as a blood pressure medicine but is not used for that: its special feature is a certain preference for the blood vessels of the brain.

NimodipineGo to the active ingredient →
NimodipineActive ingredientNimodipineCat. No. P-N067-001CAS 66085-59-4
Nimodipine-d7Isotopically labelledNimodipine-d7Cat. No. P-N067-005CAS 1246815-36-0

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Reference substanceNimodipine CRSEDQM code N0850000Family Nimodipine

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.